April 23, 2024

## **VIA EDGAR AND EMAIL**

Securities and Exchange Commission Division of Corporation Finance 100 F Street NE Washington, D.C. 20549 Attn: Tim Buchmiller

Re: Applied Therapeutics, Inc.

Registration Statement on Form S-3 (File No. 333-278182)

**Request for Acceleration of Effective Date** 

Ladies and Gentlemen:

We refer to the registration statement on Form S-3 (File No. 333-278182) (the "<u>Registration Statement</u>"), of Applied Therapeutics, Inc. (the "<u>Company</u>").

In accordance with Rules 460 and 461 under the Securities Act of 1933, as amended, the Company hereby respectfully requests that the effectiveness of the Registration Statement be accelerated so that it may become effective at 4:00 p.m. (Eastern time) on Thursday, April 25, 2024, or at such later time as the Company or its counsel may orally request via telephone call to the staff of the Division of Corporation Finance of the Securities and Exchange Commission.

Please call Michael J. Schwartz of Skadden, Arps, Slate, Meagher & Flom LLP, at (212) 735-3694, to confirm the effectiveness of the Registration Statement.

Very truly yours,

Applied Therapeutics, Inc.

By: /s/ Shoshana Shendelman

Name: Shoshana Shendelman

Title: President and Chief Executive Officer

(Principal Executive Officer)